Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merus selects Innocoll to market wound care products in Canada
Furthermore, Innocoll agrees to grant Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market. The three products are indicated
Furthermore, Innocoll agrees to grant Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market. The three products are indicated
Sun Pharma’s units have raised their equity stake in Taro to 48.7% and voting rights to 65.8%, according to reports. The acquisition is in pursuant to the option
The study is expected to recruit a total of 80 patients at investigative sites in Italy, Switzerland and South Africa. CYT107 Phase II study is designed to evaluate
In conjunction with the sublicensing agreement, Topica Pharmaceuticals will now focus on developing Luliconazole exclusively for the treatment of onychomycosis. Reportedly, in February of 2010 the company’s IND
The decision comes a year after Marubeni transferred sales and marketing of F310 Polyvinylidene Chloride (PVDC) product to Viachem from Univar’s ChemPoint business unit. Marubeni claimed that its
Tamaris is a randomised, double blind, placebo controlled study designed to evaluate the safety and efficacy of NV1FGF in patients with critical limb ischemia and skin lesions who
OctoPlus said that the undisclosed contract value will make a material contribution to its’ annual revenues. As per the contract terms, OctoPlus is expected to perform clinical manufacturing
Novartis claimed that the FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. Gilenya belongs to a new class
The MHRA inspection was conducted on the GMP side to determine whether Almac’s IXRS integrated phone and web response system was able to adequately ensure that expired products
PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio – CUSHING’S disease), a randomised study to evaluate a medical therapy in patients with Cushing’s disease, is part of a large-scale global clinical